Eladin5 mg/5 ml

Eladin 5 mg/5 ml is a second-generation antihistamine widely prescribed for fast, effective relief from allergy symptoms. It works by blocking the action of histamine, a natural substance the body produces during an allergic reaction, thereby reducing sneezing, itching, and nasal or skin irritation.

Eladin 5 mg/5 ml is commonly indicated for:

• Seasonal allergic rhinitis (hay fever) — sneezing, runny nose, and itchy or watery eyes triggered by pollen, dust, or seasonal allergens
• Perennial allergic rhinitis — year-round allergy symptoms caused by indoor allergens such as dust mites, mold, or pet dander
• Chronic idiopathic urticaria (hives) — persistent skin rashes, redness, and itching without an identifiable cause
• Other allergic skin conditions, including nettle rash and generalized itching

In children over 2 years of age, Eladin 5 mg/5 ml is used for symptomatic relief of seasonal allergic rhinitis and allergic skin conditions such as urticaria. Because it does not readily cross into the central nervous system, it provides allergy relief with a much lower risk of drowsiness compared to older first-generation antihistamines.

Non-sedating antihistamines (second-generation H1-receptor antagonists)

Eladin 5 mg/5 ml is a long-acting tricyclic antihistamine that selectively blocks peripheral histamine H1 receptors. Unlike first-generation antihistamines, it has minimal ability to cross the blood-brain barrier, which means it produces little to no central sedative or anticholinergic effects at recommended doses.

After oral administration, Eladin 5 mg/5 ml is rapidly absorbed and extensively metabolized in the liver into its active metabolite, desEladin 5 mg/5 ml, which contributes significantly to its overall antihistaminic effect. Its onset of action typically begins within 1–3 hours, reaches peak effect within 8–12 hours, and provides symptom control for a full 24 hours, allowing for convenient once-daily dosing.

Eladin 5 mg/5 ml has a favorable interaction profile compared to older antihistamines. There are no reports of clinically significant hazardous interactions with common medications. Unlike many first-generation antihistamines, Eladin 5 mg/5 ml does not produce additional sedation or impair psychomotor performance when taken along with alcohol.

However, caution is advised with drugs that inhibit or are metabolized by the hepatic cytochrome P450 enzymes (CYP3A4 and CYP2D6), as these can raise plasma concentrations of Eladin 5 mg/5 ml:

• Cimetidine — inhibits both CYP3A4 and CYP2D6 enzymes
• Erythromycin — inhibits CYP3A4
• Ketoconazole — inhibits CYP3A4

Although these interactions can increase Eladin 5 mg/5 ml serum levels, no significant adverse clinical effects have been reported in studies. Even so, patients on these medications should inform their doctor before starting Eladin 5 mg/5 ml.

Eladin 5 mg/5 ml is generally well tolerated. In controlled clinical studies, the incidence of adverse effects — including sedation and anticholinergic effects — with the standard 10 mg dose was comparable to placebo. Driving performance and cognitive-psychomotor function tests have also shown results similar to placebo, confirming its non-sedating profile.

Although uncommon, some patients may experience mild side effects such as:

• Headache
• Dry mouth
• Fatigue
• Stomach upset
• Rarely, mild drowsiness in sensitive individuals

Seek medical attention if you notice signs of a serious allergic reaction such as facial swelling, difficulty breathing, or severe skin rash.

There is limited clinical experience with Eladin 5 mg/5 ml use during human pregnancy; therefore, its use during pregnancy is not generally advisable unless considered essential by a physician.

Eladin 5 mg/5 ml is excreted in breast milk in very small amounts. Nursing mothers are advised to avoid taking this medication unless directed otherwise by a registered doctor, as safety data in lactation remain limited.

Eladin 5 mg/5 ml should be used with caution in patients with:

• Liver impairment — reduced hepatic function may slow drug metabolism
• Renal insufficiency (eGFR less than 30 mL/min) — dose adjustment may be required

Patients with these conditions should consult their physician, who may recommend a lower dose or less frequent dosing schedule (e.g., every other day) to avoid drug accumulation.

In adults, overdoses greater than 10 mg have been associated with somnolence, tachycardia (rapid heartbeat), and headache. In children, overdoses greater than 10 mg have been linked to extrapyramidal signs and palpitations.

Management of overdose includes prompt general symptomatic and supportive care, maintained for as long as clinically necessary. Oral activated charcoal may be considered in patients presenting soon after a large overdose. Inducing vomiting or performing gastric lavage may also be appropriate in conscious patients under medical supervision.

If an overdose is suspected, seek emergency medical care immediately.

• Store in a cool, dry place away from direct light and heat
• Keep the medicine in its original packaging until ready for use
• Keep out of reach of children